BMO Capital Markets Reiterates “Outperform” Rating for Neurocrine Biosciences, Inc. (NBIX)

BMO Capital Markets reaffirmed their outperform rating on shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in a research note issued to investors on Thursday morning. The firm currently has a $84.00 price objective on the stock.

A number of other research firms also recently issued reports on NBIX. Robert W. Baird reissued an outperform rating and issued a $66.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, September 21st. Jefferies Group LLC reissued a buy rating and issued a $69.00 price target (up from $66.00) on shares of Neurocrine Biosciences in a research note on Tuesday, October 3rd. BidaskClub raised shares of Neurocrine Biosciences from a sell rating to a hold rating in a research note on Wednesday, June 21st. Oppenheimer Holdings, Inc. reissued an outperform rating and issued a $70.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, July 5th. Finally, Cowen and Company reissued an outperform rating and issued a $65.00 price target (up from $60.00) on shares of Neurocrine Biosciences in a research note on Wednesday, August 9th. Two analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $68.44.

Neurocrine Biosciences (NBIX) opened at 62.44 on Thursday. The firm has a 50-day moving average of $57.19 and a 200-day moving average of $50.50. Neurocrine Biosciences has a 52 week low of $37.35 and a 52 week high of $63.77. The company’s market capitalization is $5.51 billion.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Thursday, August 3rd. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.01). The business had revenue of $6.34 million for the quarter, compared to the consensus estimate of $0.61 million. During the same quarter in the previous year, the business earned ($0.46) earnings per share. Analysts anticipate that Neurocrine Biosciences will post ($2.45) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://ledgergazette.com/2017/10/09/bmo-capital-markets-reiterates-outperform-rating-for-neurocrine-biosciences-inc-nbix.html.

In related news, insider Dimitri E. Grigoriadis sold 15,354 shares of the company’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $55.00, for a total transaction of $844,470.00. Following the sale, the insider now directly owns 123,045 shares of the company’s stock, valued at approximately $6,767,475. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Christopher Flint Obrien sold 8,734 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $50.00, for a total transaction of $436,700.00. Following the sale, the insider now directly owns 57,707 shares in the company, valued at $2,885,350. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 132,580 shares of company stock worth $7,440,850. 4.80% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in NBIX. UBS Asset Management Americas Inc. increased its stake in Neurocrine Biosciences by 3.0% during the 1st quarter. UBS Asset Management Americas Inc. now owns 595,258 shares of the company’s stock worth $25,775,000 after buying an additional 17,124 shares during the period. Karp Capital Management Corp purchased a new stake in Neurocrine Biosciences during the 1st quarter worth approximately $932,000. Parametric Portfolio Associates LLC increased its stake in Neurocrine Biosciences by 8.6% during the 1st quarter. Parametric Portfolio Associates LLC now owns 53,059 shares of the company’s stock worth $2,297,000 after buying an additional 4,212 shares during the period. Schroder Investment Management Group increased its stake in Neurocrine Biosciences by 1.7% during the 1st quarter. Schroder Investment Management Group now owns 20,496 shares of the company’s stock worth $856,000 after buying an additional 335 shares during the period. Finally, Neuberger Berman Group LLC increased its stake in Neurocrine Biosciences by 35.3% during the 1st quarter. Neuberger Berman Group LLC now owns 431,583 shares of the company’s stock worth $18,688,000 after buying an additional 112,500 shares during the period.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, fo

A number of other research firms also recently issued reports on NBIX. Robert W. Baird reissued an outperform rating and issued a $66.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, September 21st. Jefferies Group LLC reissued a buy rating and issued a $69.00 price target (up from $66.00) on shares of Neurocrine Biosciences in a research note on Tuesday, October 3rd. BidaskClub raised shares of Neurocrine Biosciences from a sell rating to a hold rating in a research note on Wednesday, June 21st. Oppenheimer Holdings, Inc. reissued an outperform rating and issued a $70.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, July 5th. Finally, Cowen and Company reissued an outperform rating and issued a $65.00 price target (up from $60.00) on shares of Neurocrine Biosciences in a research note on Wednesday, August 9th. Two analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $68.44.

Neurocrine Biosciences (NBIX) opened at 62.44 on Thursday. The firm has a 50-day moving average of $57.19 and a 200-day moving average of $50.50. Neurocrine Biosciences has a 52 week low of $37.35 and a 52 week high of $63.77. The company’s market capitalization is $5.51 billion.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Thursday, August 3rd. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.01). The business had revenue of $6.34 million for the quarter, compared to the consensus estimate of $0.61 million. During the same quarter in the previous year, the business earned ($0.46) earnings per share. Analysts anticipate that Neurocrine Biosciences will post ($2.45) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://ledgergazette.com/2017/10/09/bmo-capital-markets-reiterates-outperform-rating-for-neurocrine-biosciences-inc-nbix.html.

In related news, insider Dimitri E. Grigoriadis sold 15,354 shares of the company’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $55.00, for a total transaction of $844,470.00. Following the sale, the insider now directly owns 123,045 shares of the company’s stock, valued at approximately $6,767,475. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Christopher Flint Obrien sold 8,734 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $50.00, for a total transaction of $436,700.00. Following the sale, the insider now directly owns 57,707 shares in the company, valued at $2,885,350. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 132,580 shares of company stock worth $7,440,850. 4.80% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in NBIX. UBS Asset Management Americas Inc. increased its stake in Neurocrine Biosciences by 3.0% during the 1st quarter. UBS Asset Management Americas Inc. now owns 595,258 shares of the company’s stock worth $25,775,000 after buying an additional 17,124 shares during the period. Karp Capital Management Corp purchased a new stake in Neurocrine Biosciences during the 1st quarter worth approximately $932,000. Parametric Portfolio Associates LLC increased its stake in Neurocrine Biosciences by 8.6% during the 1st quarter. Parametric Portfolio Associates LLC now owns 53,059 shares of the company’s stock worth $2,297,000 after buying an additional 4,212 shares during the period. Schroder Investment Management Group increased its stake in Neurocrine Biosciences by 1.7% during the 1st quarter. Schroder Investment Management Group now owns 20,496 shares of the company’s stock worth $856,000 after buying an additional 335 shares during the period. Finally, Neuberger Berman Group LLC increased its stake in Neurocrine Biosciences by 35.3% during the 1st quarter. Neuberger Berman Group LLC now owns 431,583 shares of the company’s stock worth $18,688,000 after buying an additional 112,500 shares during the period.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply